2910
J. Holms et al. / Bioorg. Med. Chem. Lett. 11 (2001) 2907–2910
TACE selectivity was demonstrated across several dif-
ferent series of hydroxamate-based inhibitors0 with
compounds containing a TMP group in the P1 sub-
stituent.
Hardman, K.; Nelson, D.; Copeland, R.; Jaffee, B.; Decicco,
C. J. Med. Chem. 1998, 41, 1745.
7. Intermediate 1 was prepared according to the procedure in
ref 5, substituting pent-4-enoic acid chloride for 4-methyl-
valeric acid chloride.
8. Sheppard, G.; Florjancic, A.; Giesler, J.; Xu, L.; Guo, Y.;
Davidsen, S.; Marcotte, P.; Elmore, I.; Albert, D.; Magoc, T.;
Bouska, J.; Goodfellow, C.; Morgan, D.; Summers, J. Bioorg.
Med. Chem. Lett. 1998, 8, 3251.
9. White, A.; Bocan, T.; Boxer, P.; Peterson, J.; Schrier, D.
Curr. Pharm. Des. 1997, 3, 45.
References and Notes
1. Bemelmans, M.; van Tits, L.; Buurman, W. Crit. Rev.
Immunol. 1996, 16, 1.
2. Decicco, C. Abstracts of Papers, 221st National Meeting of
the American Chemical Society, San Diego, CA, April 1–5,
2001; American Chemical Society: Washington, DC, 2001;
MEDI 189.
3. Black, R.; Rauch, C.; Kozlosky, C.; Peschon, J.; Slack, J.;
Wolfson, M.; Castner, B.; Stocking, K.; Reddy, P.; Srinivasan,
S.; Nelson, N.; Bolani, N.; Schooley, K.; Gerhart, M.; Davis,
R.; Fitzner, J.; Johnson, R.; Paxton, R.; March, C.; Cerretti,
D. Nature 1997, 385, 729.
4. (a) McGeehan, G.; Becherer, J.; Bast, R.; Boyer, C.;
Champion, B.; Connolly, K.; Conway, J.; Furdon, P.; Karp,
S.; Kidao, S.; McElroy, A.; Nichols, J.; Pryzwansky, K.;
Schoenen, F.; Sekut, L.; Truesdale, A.; Verghese, M.; Warner,
J.; Ways, J. Nature 1994, 370, 558. (b) Gearing, A.; Beckett,
M.; Christodoulou, M.; Churchill, M.; Clements, J.; David-
son, A.; Drummond, A.; Galloway, W.; Gilbert, R.; Gordon,
J.; Leber, T.; Mangan, M.; Miller, K.; Nayee, P.; Owens, K.;
Patel, S.; Thomas, W.; Wells, G.; Wood, L.; Wooley, K. Nat-
ure 1994, 370, 555.
10. Maskos, K.; Fernandez-Catalan, C.; Huber, R.; Bour-
enkov, G.; Bartunik, H.; Ellestad, G.; Reddy, P.; Wolfson, M.;
Rauch, C.; Castner, B.; Davis, R.; Clarke, H.; Petersen, M.;
Fitzner, J.; Cerretti, D.; March, C.; Paxton, R.; Black, R.;
Bode, W. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3408.
11. A soluble form of TACE, lacking the carboxyterminal
membrane binding domain, was produced from a baculovirus
expression system. The secreted, active enzyme was partially
purified using Q-Sepharose and hydroxyapatite chromato-
graphy. TACE inhibition was assessed in a microtiter plate
format by a protocol similar to that used for MMP assays,
using a TACE specific fluorogenic substrate, Acetyl-Gly-
Glu(EDANS)-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser Lys(DAB-
CYL)-Gly-NH2, in 10 mM Tris–HCl, 1 mM MgCl2, pH 7.4.
12. Marcotte, P.; Davidsen, S. In Current Protocols in Phar-
macology; Enna, S., Williams, M., Ferkany, J., Kenakin, T.,
Porsolt, R., Sullivan, J., Eds.; John Wiley and Sons: New
York, 2001; p 3.7.1.
13. Glaser, K.; Pease, L.; Li, J.; Morgan, D. Biochem. Phar-
macol. 1999, 57, 291.
14. Zook, S.; Dagnino, R.; Deason, M.; Bender, S.; Melnick,
M. PCT Patent Application WO 97/20824.
15. Warpehoski, M.; Harper, D. PCT Patent Application WO
98/13340.
5. Steinman, D.; Curtin, M.; Garland, R.; Davidsen, S.; Hey-
man, R.; Holms, J.; Albert, D.; Magoc, T.; Nagy, I.; Marcotte,
P.; Li, J.; Morgan, D.; Hutchins, C.; Summers, J. Bioorg. Med.
Chem. Lett. 1998, 8, 2087.
6. Xue, C.; He, X.; Roderick, J.; DeGrado, W.; Cherney, R.;